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Multiple Sclerosis and Venous Abnormalities: Medicine
in the Age of Social MediaMultiple sclerosis (MS) is an inflammatory, demyelin-
ating disease considered by most who are expert in the field
to have an autoimmune origin. However, a small number of
investigators have postulated a vascular association since the
time of the first histologic description of MS by Charcot [1].
A central vein can be seen by magnetic resonance (MR)
venography in MS plaques [2], and results of other imaging
studies have indicated a correlation between the location of
MS lesions and venous structures [3,4]. In 2009, these
theories of a vascular association gathered prominence after
2 publications by Professor Paolo Zamboni from Ferrara,
Italy [5,6]. In his publications, Zamboni coined the term
chronic cerebrospinal venous insufficiency (CCSVI) to
describe a constellation of extracranial venous obstructions
that he observed in patients with MS, and the treatment of
this disorder has been labelled the ‘‘Liberation Procedure.’’
The first article [5], an unblinded nonrandomized study
described 4 patterns of venous abnormalities in 65 of 65
patients with MS and in 0 of 48 patients in a control group,
which consisted of healthy subjects and patients with
neurologic diseases other than MS. The article reported
a 100% sensitivity, specificity, positive predictive value, and
negative predictive value. He classified these abnormalities
as type A, stenosis of the proximal azygos associated with
stenosis of 1 of the 2 internal jugular veins; type B, bilateral
stenosis of internal jugular veins and proximal azygos
stenosis; type C, bilateral stenosis of the internal jugular
veins, with a normal azygos venous system; and type D,
various stenoses of the azygos system. Zamboni’s hypothesis
is that impaired venous drainage from chronic cerebrospinal
venous insufficiency leads to iron deposition in interstitial
brain tissue, which has a role in the pathogenesis of MS.
Increased iron density in MS plaques has been suggested by
susceptibility-weighted imaging [7].
In November 2009, Zamboni published an open-label
intervention study of endovascular treatment of CCSVI and
reported significant improvement in disease severity outcome
measures in the same patient population, particularly the
subgroup of patients with a relapsing remitting type ofMS [6].
Treatment included both angioplasty and stenting, although
the numbers of each and their precise locations were not
specified in the publication. The outcomes were reportedDisclosures: The authors have no conflicts of interest to disclose.
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group. The proportion of patients who were relapse free
changed from 27% to 50% and those with gadolinium-
enhancing lesions on magnetic resonance imaging decreased
from 50% to 12%. The Multiple Sclerosis Functional
Composite Index at 1 year improved in patients with relapsing
remitting MS but not in those with primary or secondary
progressive disease. Physical quality of life scale improved in
patients with relapsing remitting and primary progressive
disease, and a positive trend was seen in those with secondary
progressive disease. Mental quality of life scale also improved
in patients with relapsing remitting and primary progressive
disease but not in secondary progressive MS.
To summarize, an intriguing small single-centre body of
work was published that described a possible advance in the
management of a serious chronic progressive and disabling
disease. Effective treatments exist that prevent disease
progression and relapses. However, there are no effective
treatments for reversing chronic disability, and only limited
treatments for improving common symptoms, such as fatigue
and bladder dysfunction. As is typical with a new minimally
invasive treatment, the first report was not a randomized or
blinded trial. In the normal course of clinical development,
the data, hypothesis, and treatment techniques would be
discussed, analysed, and modified, and the data confirmed or
refuted by further independent studies, optimally controlled,
randomized, and multicentre. However, Zamboni’s work
[5,6] was widely reported in the Canadian popular press, and,
to say the least, considerable interest has been generated
within a very electronically connected MS community.
Patients demanded and have been frustrated that the Cana-
dian health care system was not able to immediately offer the
‘‘Liberation Procedure’’ to them. MS experts nationally and
globally have generally discounted Zamboni’s work as
a scientifically unsound theory, with clinical results not
unexpected from the placebo effect commonly seen in
unblinded, uncontrolled MS studies. In each province,
departments of health and medical licensing boards have
determined that there is insufficient evidence on efficacy and
safety to allow this procedure as part of routine care for
Canadian patients with MS. These events have been a vivid
lesson to the medical community about the impacts of social
media, electronic communication, and a society increasingly
accustomed to instant access to everything. Thell rights reserved.
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collision exacerbated by the following additional issues:
 Canada has one of the highest per capita incidences of
MS in the world; more than 60,000 Canadians are
affected.
 MS is a unique disease in the degree to which symptoms
can wax and wane. There can be a significant placebo
effect in controlled MS trials, for example, ranging from
30%-50% improvement in annualized relapse rates [8]
 At the time of writing, there are no data on the incidence
of stenoses in the jugular veins of the general population
or outcomes of endovenous jugular venous interventions
of any type, let alone controlled trials in CCSVI.
 There is no consensus as to what constitutes a jugular
vein stenosis, best modality for diagnosis, how to treat
a primary stenosis, how to prevent or treat restenosis, or
optimal methods of follow-up.
 A cash-strapped heavily-controlled public health care
system that, by its unique design, has never easily
adapted to new minimally invasive therapies increasingly
demands a higher burden of proof before incorporating
new therapies. Patients who wish to obtain treatments
that have not yet been approved frequently do not
understand how limited the ability is for physicians to
affect change within this system.
 Every new development, real and rumored, is distributed
throughout the world via social networks. Physicians,
administrators, and politicians are being asked to respond
to new developments, sometimes within hours of their
first discussion.
 MS neurologists are conservative as a group and tend to
demand high levels of proof for any therapy. Neurolo-
gists are extremely aware of the high incidence of
placebo effect in MS trials. There have been prior
treatments, for example, hyperbaric oxygen therapy,
which initially looked so promising that it warranted
publication in the New England Journal of Medicine, but
subsequently proved ineffective [9]. Endovascular ther-
apists tend to be ‘‘can do’’ personalities and work in
a discipline in which such stringent levels of documen-
tation are often not available or even possible. Most
endovascular therapies that required a 5-year study
would be outdated by the time the study was over.Radiologists in Canada Are Faced With 3 Distinct
ProblemsPatients Requesting Investigation for CCSVIThere is considerable debate as to whether CCSVI exists
as an entity, let alone whether it affects the pathogenesis of
MS. If one examines the jugular veins by using the techniques
commonly performed to diagnose venous insufficiency in the
lower extremities, then subtle abnormalities will be found in
virtually all patients, whether or not they have MS. Thesignificance of these abnormalities are hard to define.
Zamboni’s ultrasound technique [5,6] is a nuanced exami-
nation, in the our opinion, which requires special instruction
and considerable practice, even for those with extensive
vascular imaging experience. There is uncertain direction
from the various provincial health ministries as to whether
investigation for CCSVI is allowed within the public system.Patients Requesting Treatment for CCSVIThe Canadian Interventional Radiology Association and
Canadian Society of Vascular Surgery both consider treat-
ment for CCSVI to be unproven and recommend it only be
offered within the context of a clinical trial. To our knowl-
edge, there are no ongoing therapeutic trials in Canada. We
strongly recommend that a sham-controlled, randomized,
prospective trial of angioplasty be conducted as soon as
possible. We recognize and respect the differing opinions
among the research community on how much time and
funding should be spent addressing the validity of this theory
and treatment. The scientific rationale and current level of
evidence that surrounds the theory that CCSVI exists and
contributes significantly to the pathogenesis and/or symp-
toms of MS is clearly not complete. In Canada, we are facing
an unprecedented number of individuals with MS who are
seeking out of country treatment by ‘‘for profit’’ centres,
many of which use questionable diagnostic, treatment, and
follow-up criteria. CCSVI research should include well-
designed trials that address pressing public health concerns,
even when there may not yet a robust body of scientific
evidence.Patients Treated for CCSVI out of Country and
Requesting Investigation and Care After Returning to
CanadaAt the time of this writing, there are no standardized
protocols for antiplatelet therapy after jugular venous inter-
vention. The most commonly used pharmaceutical regimen
after peripheral vascular stent insertion is clopidogrel 325 mg
by mouth daily for 1-3 months and acetylsalicylic acid 80 mg
by mouth daily for life. We recommend that this or another
protocol of choice to local interventionists be distributed to
their local MS neurologists. At the time of writing, there are
no standardized protocols for follow-up after jugular venous
intervention. We believe that the most important issue is that
patients continue routine MS care from their neurologist.
Defining a program for timing and method of imaging
follow-up is more problematic:
I. If the patient has been treated with a stent, then we
recommend the following:
a. The patient is obligated to provide details about the
size, number, and type of stent(s) before any
follow-up imaging.
b. A radiograph and/or ultrasound are recommended
to document the position of the stent(s); there has
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for CCSVI that migrated into the heart.
c. There are no data on how long a period must pass
before a jugular venous stent can be considered
stable. The frequency and duration of surveillance
is unknown at this time.
d. Because of the risk of stent migration into the
heart, the patient should be advised by his or her
neurologist to seek medical attention for chest pain,
palpitations, or neck pain. Neck and chest radio-
graph should be considered if these occur.
e. There are a number of patients for whom an
ultrasound has been interpreted as showing ‘‘clot
within the stent.’’ There is no other area of the body
where stents are so close to the skin surface and
thus seen in such detail on ultrasound as the jugular
vein. One of us (L.M.) has been sent images of 3
patients with this tentative diagnosis; in each case,
the findings were clearly of intimal hyperplasia,
and no clot was seen. It is not clear at this time if
clot formation is a common event.
f. It is not clear whether imaging should include
assessment for restenosis. At this time, the natural
history of intimal hyperplasia (the biologic process
of restenosis after endovascular procedures) in
jugular venous stents is unknown. When found,
there is no proven method for treatment of jugular
vein in-stent restenosis. Candidate therapies
include insertion of a stent within a stent or
a covered stent. These considerably ‘‘up the ante,’’
because they may require lifetime clopidogrel
therapy and increase the risk of central migration.
These risks are difficult to balance against benefit
when definitive proof that endovascular treatment
of CCSVI alters the clinical course of MS has not
yet been achieved. Although abrupt surgical jugular
vein ligation has not resulted in untoward
morbidity, it is not clear if jugular venous stent
occlusion is also innocuous.
II. Physicians in Canada are obligated to treat complica-
tions regardless of where an original procedure was
done. If a stent migrates into the heart, then none of us
are confused about our duties to the patient. More
problematic is that there has not been consistent
direction from Canadian regulatory bodies regarding
how to care for patients in the public system who
initially perceived benefit after endovascular treatment
for CCSVI, then have a return of their symptoms.
Symptom recurrence in patients who have had treat-
ment for CCSVI could potentially happen for 2 reasons.
One is that the perceived benefit was placebo effect (see
above). The second is that there actually was a treat-
ment effect and that the angioplasty or stent has
renarrowed (restenosis). Most patients assume the
latter. As stated above, there are no data on restenosis
after jugular vein interventions, and we certainly do not
have data on the best method to treat it.Summary
We are experiencing a unique medical issue that has been
exacerbated by the new reality of near instantaneous sharing
of information. MS is a terrible disease, and patients deserve
our compassion and understanding when they hear reports of
a possible treatment and want to act upon it. Less obvious to
many patients is the extremely limited knowledge base about
the diagnosis of CCSVI or consequences of endovenous
jugular vein interventions and the lack of a robust therapy for
jugular vein stenosis. Our obligation to these patients is to
ensure they are made aware of these facts, advise that, for the
immediate future, any interventions performed should ideally
be within properly performed clinical trials and wherever
possible advocate for the earliest possible funding of these
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